Cargando…
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
[Image: see text] Thiazoles exhibit a wide range of biological activities and therefore represent useful and attractive building blocks. To evaluate their usefulness and pinpoint their liabilities in fragment screening campaigns, we assembled a focused library of 49 fragment-sized thiazoles and thia...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743419/ https://www.ncbi.nlm.nih.gov/pubmed/36518695 http://dx.doi.org/10.1021/acsmedchemlett.2c00429 |
_version_ | 1784848722901860352 |
---|---|
author | Proj, Matic Hrast, Martina Knez, Damijan Bozovičar, Krištof Grabrijan, Katarina Meden, Anže Gobec, Stanislav Frlan, Rok |
author_facet | Proj, Matic Hrast, Martina Knez, Damijan Bozovičar, Krištof Grabrijan, Katarina Meden, Anže Gobec, Stanislav Frlan, Rok |
author_sort | Proj, Matic |
collection | PubMed |
description | [Image: see text] Thiazoles exhibit a wide range of biological activities and therefore represent useful and attractive building blocks. To evaluate their usefulness and pinpoint their liabilities in fragment screening campaigns, we assembled a focused library of 49 fragment-sized thiazoles and thiadiazoles with various substituents, namely amines, bromides, carboxylic acids, and nitriles. The library was profiled in a cascade of biochemical inhibition assays, redox activity, thiol reactivity, and stability assays. Our study indicates that when thiazole derivatives are identified as screening hits, their reactivity should be carefully addressed and correlated with specific on-target engagement. Importantly, nonspecific inhibition should be excluded using experimental approaches and in silico predictions. To help with validation of hits identified in fragment screening campaigns, we can apply our high-throughput profiling workflow to focus on the most tractable compounds with a clear mechanism of action. |
format | Online Article Text |
id | pubmed-9743419 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-97434192022-12-13 Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe? Proj, Matic Hrast, Martina Knez, Damijan Bozovičar, Krištof Grabrijan, Katarina Meden, Anže Gobec, Stanislav Frlan, Rok ACS Med Chem Lett [Image: see text] Thiazoles exhibit a wide range of biological activities and therefore represent useful and attractive building blocks. To evaluate their usefulness and pinpoint their liabilities in fragment screening campaigns, we assembled a focused library of 49 fragment-sized thiazoles and thiadiazoles with various substituents, namely amines, bromides, carboxylic acids, and nitriles. The library was profiled in a cascade of biochemical inhibition assays, redox activity, thiol reactivity, and stability assays. Our study indicates that when thiazole derivatives are identified as screening hits, their reactivity should be carefully addressed and correlated with specific on-target engagement. Importantly, nonspecific inhibition should be excluded using experimental approaches and in silico predictions. To help with validation of hits identified in fragment screening campaigns, we can apply our high-throughput profiling workflow to focus on the most tractable compounds with a clear mechanism of action. American Chemical Society 2022-11-03 /pmc/articles/PMC9743419/ /pubmed/36518695 http://dx.doi.org/10.1021/acsmedchemlett.2c00429 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Proj, Matic Hrast, Martina Knez, Damijan Bozovičar, Krištof Grabrijan, Katarina Meden, Anže Gobec, Stanislav Frlan, Rok Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe? |
title | Fragment-Sized
Thiazoles in Fragment-Based Drug Discovery
Campaigns: Friend or Foe? |
title_full | Fragment-Sized
Thiazoles in Fragment-Based Drug Discovery
Campaigns: Friend or Foe? |
title_fullStr | Fragment-Sized
Thiazoles in Fragment-Based Drug Discovery
Campaigns: Friend or Foe? |
title_full_unstemmed | Fragment-Sized
Thiazoles in Fragment-Based Drug Discovery
Campaigns: Friend or Foe? |
title_short | Fragment-Sized
Thiazoles in Fragment-Based Drug Discovery
Campaigns: Friend or Foe? |
title_sort | fragment-sized
thiazoles in fragment-based drug discovery
campaigns: friend or foe? |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743419/ https://www.ncbi.nlm.nih.gov/pubmed/36518695 http://dx.doi.org/10.1021/acsmedchemlett.2c00429 |
work_keys_str_mv | AT projmatic fragmentsizedthiazolesinfragmentbaseddrugdiscoverycampaignsfriendorfoe AT hrastmartina fragmentsizedthiazolesinfragmentbaseddrugdiscoverycampaignsfriendorfoe AT knezdamijan fragmentsizedthiazolesinfragmentbaseddrugdiscoverycampaignsfriendorfoe AT bozovicarkristof fragmentsizedthiazolesinfragmentbaseddrugdiscoverycampaignsfriendorfoe AT grabrijankatarina fragmentsizedthiazolesinfragmentbaseddrugdiscoverycampaignsfriendorfoe AT medenanze fragmentsizedthiazolesinfragmentbaseddrugdiscoverycampaignsfriendorfoe AT gobecstanislav fragmentsizedthiazolesinfragmentbaseddrugdiscoverycampaignsfriendorfoe AT frlanrok fragmentsizedthiazolesinfragmentbaseddrugdiscoverycampaignsfriendorfoe |